Join
Live feed
·
PRReleasevia Quantisnow
Apogee Therapeutics Inc. logo

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

ByQuantisnow·Wall Street's wire, on your screen.
APGE· Apogee Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track APGE (Apogee Therapeutics Inc.) and more on Quantisnow.